{"hq_id":"hq-c-org-002105","name":"Terbinafine","context":"human_adult","risk_level":"moderate","schema":"legacy","note":"Synthesis unavailable: compound lacks vectorizable regulatory classifications. Raw safety data returned.","data":{"risk_level":"moderate","summary":"Terbinafine is an allylamine antifungal used primarily for dermatophyte infections (onychomycosis, tinea corporis/pedis/capitis). Mechanism: inhibits squalene epoxidase, an early enzyme in ergosterol biosynthesis, causing squalene accumulation and ergosterol depletion in fungal membranes. First-line oral treatment for onychomycosis: 250 mg/day for 6 weeks (fingernails) or 12 weeks (toenails), cure rate ~70-80%. Key safety concerns: hepatotoxicity — FDA issued a safety warning in 2001 after post-marketing reports of liver failure (including fatal cases and transplant requirements); incidence estimated at 1 in 50,000-120,000 treatment courses. Liver function testing recommended before and during treatment. Taste disturbance (dysgeusia/ageusia) occurs in 0.5-2.8% of patients and can persist for weeks to months after discontinuation; may be permanent in rare cases. Other adverse effects: headache, GI symptoms, rash, rarely Stevens-Johnson syndrome. Drug interactions: CYP2D6 inhibitor — caution with SSRIs, tricyclics, beta-blockers. Well-tolerated topically (Lamisil cream/spray) with minimal systemic absorption.","source_refs":["aletheia_fungi_batch_2026"]},"meta":{"synthesis_version":"n/a","timestamp":"2026-07-27T02:35:29.148Z"},"_notice":"ALETHEIA output is reference data, not professional advice. Not a substitute for primary agency sources or qualified professionals. See https://aletheia.holisticquality.io/disclaimer.","_disclaimer_url":"https://aletheia.holisticquality.io/disclaimer","available_contexts":["human_adult"]}